According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Shanon and William Schmidtknecht, of Poynette, say their 22-year-old son Cole was told the cost had jumped from $66 to $539 ...

A Wisconsin couple is suing Walgreens and a pharmacy benefits company alleging their son died because he couldn't afford a ...

Dexamphetamine—a restricted stimulant drug used to treat narcolepsy and Attention Deficient Hyperactivity Disorder ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

A NEWLY developed diagnostic tool is set to transform the identification of cough variant asthma (CVA), a condition where chronic cough is the primary symptom. With traditional bronchial provocation ...

Its leading drugs include Lantus for treating diabetes and Dupixent for treating atopic dermatitis, asthma and chronic ... from the FDA and is under review in the U.K. and E.U. Hellweg projects ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

both of which are positioned for indication expansions into severe asthma and COPD. The first biologic to enter the COPD market, Dupixent (dupilumab), has paved the way for competitors ...